[go: up one dir, main page]

RS62975B1 - In vitro postupak za povećanje nivoa izlučivanja interleukina 2 i iz njega izvedenih proteina - Google Patents

In vitro postupak za povećanje nivoa izlučivanja interleukina 2 i iz njega izvedenih proteina

Info

Publication number
RS62975B1
RS62975B1 RS20220217A RSP20220217A RS62975B1 RS 62975 B1 RS62975 B1 RS 62975B1 RS 20220217 A RS20220217 A RS 20220217A RS P20220217 A RSP20220217 A RS P20220217A RS 62975 B1 RS62975 B1 RS 62975B1
Authority
RS
Serbia
Prior art keywords
interleukin
increasing
vitro method
proteins derived
secretion levels
Prior art date
Application number
RS20220217A
Other languages
English (en)
Inventor
Dorantes Gertrudis Rojas
Monzón Kalet León
Portilla Tania Carmenate
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of RS62975B1 publication Critical patent/RS62975B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
RS20220217A 2016-11-15 2017-11-10 In vitro postupak za povećanje nivoa izlučivanja interleukina 2 i iz njega izvedenih proteina RS62975B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2016000171A CU24483B1 (es) 2016-11-15 2016-11-15 Método para incrementar los niveles de secreción de la interleucina-2
PCT/CU2017/050007 WO2018091003A1 (es) 2016-11-15 2017-11-10 Método para incrementar los niveles de secreción de la interleucina 2 y sus proteínas derivadas
EP17817648.3A EP3543252B1 (en) 2016-11-15 2017-11-10 In vitro method for increasing the secretion levels of interleukin 2 and proteins derived from it

Publications (1)

Publication Number Publication Date
RS62975B1 true RS62975B1 (sr) 2022-03-31

Family

ID=60765569

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220217A RS62975B1 (sr) 2016-11-15 2017-11-10 In vitro postupak za povećanje nivoa izlučivanja interleukina 2 i iz njega izvedenih proteina

Country Status (23)

Country Link
US (1) US20190315826A1 (sr)
EP (1) EP3543252B1 (sr)
JP (1) JP6918405B2 (sr)
KR (1) KR102525674B1 (sr)
CN (1) CN109952311B (sr)
AR (1) AR110076A1 (sr)
AU (1) AU2017359841B2 (sr)
BR (1) BR112019009106A2 (sr)
CA (1) CA3040313A1 (sr)
CO (1) CO2019004006A2 (sr)
CU (1) CU24483B1 (sr)
EA (1) EA201991093A1 (sr)
ES (1) ES2906832T3 (sr)
IL (1) IL266517A (sr)
JO (1) JOP20190087A1 (sr)
MX (1) MX2019005599A (sr)
MY (1) MY197059A (sr)
RS (1) RS62975B1 (sr)
TN (1) TN2019000122A1 (sr)
TW (1) TWI713798B (sr)
UA (1) UA125440C2 (sr)
WO (1) WO2018091003A1 (sr)
ZA (1) ZA201902968B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
JP7490563B2 (ja) * 2018-03-28 2024-05-27 アセンディス ファーマ オンコロジー ディヴィジョン エー/エス Il-2コンジュゲート
EA202092316A1 (ru) 2018-03-28 2021-05-25 Бристол-Маерс Сквибб Компани Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
CN112771072B (zh) * 2018-07-24 2025-01-07 生物技术公司 Il2激动剂
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
WO2021245130A1 (en) 2020-06-03 2021-12-09 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
US12024559B2 (en) 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
EP4236962A1 (en) 2020-10-29 2023-09-06 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
CN116854802A (zh) * 2021-04-13 2023-10-10 苏州复融生物技术有限公司 白介素2突变体及其应用
WO2022260909A1 (en) * 2021-06-09 2022-12-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods of using anti-cd83 chimeric antigen receptor expressing t cells
CU20210104A7 (es) 2021-12-21 2023-07-12 Ct Inmunologia Molecular Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
CU20220020A7 (es) 2022-03-18 2023-12-07 Ct Inmunologia Molecular Muteínas derivadas de la interleucina-2 humana con actividad superagonista
TW202409069A (zh) * 2022-07-01 2024-03-01 大陸商北京星奇原生物科技有限公司 Il-2多肽和使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
MX2007009012A (es) * 2005-01-27 2007-09-14 Novartis Vaccines & Diagnostic Metodos para tratar carcinoma de celulas renales.
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
RS57767B1 (sr) * 2011-02-10 2018-12-31 Roche Glycart Ag Mutantni interleukin-2 polipeptidi
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2

Also Published As

Publication number Publication date
IL266517A (en) 2019-07-31
KR102525674B1 (ko) 2023-04-25
JP6918405B2 (ja) 2021-08-11
US20190315826A1 (en) 2019-10-17
MY197059A (en) 2023-05-23
MX2019005599A (es) 2019-07-04
WO2018091003A1 (es) 2018-05-24
BR112019009106A2 (pt) 2019-07-16
ZA201902968B (en) 2020-07-29
CN109952311A (zh) 2019-06-28
NZ753820A (en) 2021-09-24
EP3543252A1 (en) 2019-09-25
ES2906832T3 (es) 2022-04-20
TWI713798B (zh) 2020-12-21
CU24483B1 (es) 2020-04-02
KR20190079636A (ko) 2019-07-05
JOP20190087A1 (ar) 2019-04-18
TW201831688A (zh) 2018-09-01
AU2017359841A1 (en) 2019-06-13
EA201991093A1 (ru) 2019-09-30
CO2019004006A2 (es) 2019-04-30
CN109952311B (zh) 2022-07-01
CU20160171A7 (es) 2018-06-05
AU2017359841B2 (en) 2020-08-27
AR110076A1 (es) 2019-02-20
JP2019535269A (ja) 2019-12-12
TN2019000122A1 (en) 2020-10-05
EP3543252B1 (en) 2021-12-29
CA3040313A1 (en) 2018-05-24
UA125440C2 (uk) 2022-03-09

Similar Documents

Publication Publication Date Title
RS62975B1 (sr) In vitro postupak za povećanje nivoa izlučivanja interleukina 2 i iz njega izvedenih proteina
ZA201808352B (en) Pegylated porcine interferon and methods of use thereof
PT3235830T (pt) Complexo proteico de interleucina 15 e sua utilização
HUP1500363A2 (en) Method for increasing the galactose content of recombinant proteins
IL270772A (en) Transplanted cytokine antibody proteins and methods of use for disorders related to the immune system
ZA202202259B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
PL3348273T3 (pl) Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych
IL287601A (en) Variant cd80 proteins and their uses
GB201819200D0 (en) Polypeptide and uses thereof
IL272837A (en) A process for preparing tubolysins and their intermediates
IL259583A (en) Collagen preparations 7 and methods of using them
EP3319930A4 (en) METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
IL269751A (en) CLPB-derived proteins and their uses
EP3542143C0 (en) RHEOMETER AND METHOD OF USE THEREOF
GB201803240D0 (en) Methods and compositions for enriching nucleic acids
IL281090A (en) Alternative processes for the preparation of tubolysins and their intermediates
IL282455A (en) Methods and preparations for the treatment of secretory disorders
IL282245A (en) Methods and compositions of polypeptide-based vaccines
GB201619965D0 (en) Immunogenic compositions comprising sbi protein and uses thereof
EP3270985A4 (en) Polypeptide compositions and methods of using the same
HUP1700012A2 (en) Novel proteins and use thereof
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
IL275377A (en) Preparations containing stabilized oxygen and methods for their creation
IL268844A (en) Peptides and methods of treating dystrophy-related diseases by them
EP3641729A4 (en) FURAZIDINE COMPOSITION IN THE FORM OF SUSPENSION AND MANUFACTURING METHOD FOR IT